Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefazolin Prophylaxis Dosing in Obese Patients
NCT01886742Phase 4Withdrawn
- Sponsor
- University of Colorado Denver
- Start
- Sep 2017
- Primary completion
- Oct 2018
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised trial of cefazolin in surgical site infection (SSI) (2 arms), sponsored by University of Colorado Denver. Primary endpoint: Assessment of the Pharmacokinetics of Cefazolin in the Morbidly Obese. Planned start Sep 2017; status: withdrawn.
02
Drugs
cefazolin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT01886742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01886742.